Biologics Sign On Letter 2019

Tuesday September 17, 2019

Dear Chairman Alexander and Ranking Member Murray:

On behalf of the undersigned organizations, we write to express urgent concern about a proposal in the President’s budget request that would undermine trust in the quality of biologic medicines with healthcare practitioners and patients, including for medicines widely prescribed to treat diabetes, rheumatoid arthritis, cancer, Crohn’s disease and colitis, and other diseases. The proposal, contained in the HELP discussion draft, would exclude biologic medicines from the requirement that all medicines marketed in the United States adhere to quality standards established by the United States Pharmacopeia (USP). We believe that USP standards have been, and should remain, a foundational element in the framework ensuring that the medicine supply in the United States is among the safest in the world.

In the last Congress, a similar proposal was rejected after robust engagement from numerous stakeholders during consideration of the 21st Century Cures Act. We are alarmed that the proposal is being reexamined and could find its way into legislation to be considered by the HELP or Appropriations Committees this year. We respectfully urge that this proposal not be further considered and not be included in any legislation amending the Public Health Service Act (PHSA) or any other provision of law or appropriations legislation.

The proposal set forth in the President’s budget request is framed as one that will lower drug costs by accelerating the development of biologic medicines, including biosimilars, with no data or rationale to support such a statement. We urge Congress to focus on resolving issues that could accelerate the availability of affordable, quality medicines for patients rather than reexamining this proposal, which poses a risk to the quality of medicines and could potentially hinder patient access.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.